Research analysts at StockNews.com assumed coverage on shares of MEI Pharma (NASDAQ:MEIP – Get Free Report) in a report issued on Wednesday. The brokerage set a “buy” rating on the stock.
Other equities analysts have also issued reports about the stock. Brookline Capital Management lowered shares of MEI Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 22nd. Laidlaw cut MEI Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Three research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $7.00.
Check Out Our Latest Analysis on MEI Pharma
MEI Pharma Stock Up 2.8 %
MEI Pharma (NASDAQ:MEIP – Get Free Report) last posted its earnings results on Thursday, September 19th. The company reported ($1.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.48) by $0.35. As a group, equities analysts expect that MEI Pharma will post -5.1 earnings per share for the current year.
Institutional Trading of MEI Pharma
An institutional investor recently raised its position in MEI Pharma stock. National Bank of Canada FI increased its holdings in shares of MEI Pharma, Inc. (NASDAQ:MEIP – Free Report) by 43.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 33,000 shares of the company’s stock after acquiring an additional 10,000 shares during the period. National Bank of Canada FI owned approximately 0.50% of MEI Pharma worth $94,000 as of its most recent SEC filing. Institutional investors own 52.38% of the company’s stock.
MEI Pharma Company Profile
MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
See Also
- Five stocks we like better than MEI Pharma
- Investing in Travel Stocks Benefits
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- Industrial Products Stocks Investing
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- Why Are Stock Sectors Important to Successful Investing?
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.